drugset
drugset / Trial / NCT04185363

An Extension Study of Maralixibat in Patients With Progressive Familial Intrahepatic Cholestasis (PFIC)

NCT04185363 ↗

Phase 3 Completed 84 enrolled Mirum Pharmaceuticals, Inc.
NaSingle-groupOpen-labelTreatment

Summary

The primary objective of this open label extension study is to evaluate the long-term safety and tolerability of maralixibat.

Timeline

Start
2020-01-08
Primary completion
2025-04-23
Completion
2025-04-23

Drugs

EvaluationDrugModalityDoseRoute
Subject Maralixibat Small molecule 600 ug/kg Oral

Indications

progressive familial intrahepatic cholestasis